Advertisement
BMY vs PFE
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- Bristol-Myers Squibb (BMY) has delivered a roughly 32% one-year return as of mid-July 2026, significantly outpacing Pfizer (PFE), which posted a single-digit gain over the same period.
- BMY's Growth Portfolio — led by Opdivo, Breyanzi, Reblozyl, and Camzyos — grew 18% year-over-year in its latest reported quarter, helping offset continued erosion in its Legacy Portfolio from generic competition.
- Pfizer offers a substantially higher dividend yield of approximately 6.9%, compared to BMY's roughly 4.2%, making it a potential candidate for income-focused investors despite weaker price momentum.
- Both companies face patent cliffs, but BMY's newer drug launches have demonstrated stronger revenue replacement momentum than Pfizer's post-COVID pipeline transition.
- Pfizer's $10 billion acquisition of Metsera signals a strategic push into the obesity drug market, a high-growth therapeutic area that could reshape its long-term growth trajectory.
- On valuation, both stocks trade at compressed forward P/E (price-to-earnings) ratios below 10x, reflecting the market's skepticism about near-term pharmaceutical growth amid policy and competitive pressures.
Introduction
Few rivalries in the pharmaceutical sector are as structurally intertwined as that between BMY and PFE. The two companies co-market Eliquis, one of the world's top-selling cardiovascular drugs, yet compete across oncology, immunology, and increasingly in metabolic disease. For investors weighing large-cap pharmaceutical exposure, the choice between these two names represents a broader debate: does one favor the stronger recent momentum and Growth Portfolio execution at Bristol-Myers Squibb, or the higher dividend yield and obesity-focused turnaround narrative at Pfizer? This comparison examines both stocks across business fundamentals, recent performance, relative positioning, and what an AI-driven analytical framework might discern.
BMY Overview and Recent Performance
Bristol-Myers Squibb discovers, develops, and markets biopharmaceutical products across oncology, hematology, cardiovascular, and immunology. The company derives nearly 70% of its revenue from the U.S. market, making it more domestically concentrated than many peers. In recent quarters, BMY's narrative has been defined by a two-speed portfolio: a fast-growing "Growth Portfolio" and a declining "Legacy Portfolio" facing generic competition.
The Growth Portfolio — anchored by immuno-oncology drug Opdivo, CAR-T cell therapy Breyanzi, anemia treatment Reblozyl, and cardiovascular drug Camzyos — generated approximately $6.6 billion in its most recently reported quarter, representing 18% year-over-year growth. Breyanzi sales alone surged 125%, while Camzyos grew 87%. Meanwhile, the Legacy Portfolio, which includes Revlimid, Pomalyst, and Sprycel, continues to contract under generic erosion and the impact of the U.S. Medicare Part D redesign, declining roughly 14%.
BMY shares have appreciated approximately 32% over the past year, reflecting market confidence in the Growth Portfolio's capacity to absorb Legacy declines. The company raised its full-year revenue guidance in its most recent earnings release and maintains a strong free cash flow yield. A strategic partnership with BioNTech (BNTX) has further expanded its pipeline in immuno-oncology. With a beta of approximately 0.23, BMY exhibits very low volatility relative to the broader market.
PFE Overview and Recent Performance
Pfizer is one of the world's largest biopharmaceutical companies, with a diversified portfolio spanning vaccines, oncology, rare diseases, immunology, and cardiovascular/metabolic treatments. The company's revenue base is more globally distributed than BMY's, and its product lineup includes blockbusters such as the Prevnar pneumococcal vaccine franchise, Ibrance, Xtandi, and the Eliquis profit-sharing arrangement with Bristol-Myers Squibb.
Pfizer's recent market activity has been shaped by the prolonged post-COVID revenue normalization. After pandemic-era revenues peaked above $100 billion in 2022, annual sales settled around $62–$64 billion in 2024 and 2025. The company has been actively reshaping its pipeline, most notably through the $10 billion acquisition of Metsera, an obesity-drug developer, signaling a clear strategic pivot toward the high-growth metabolic disease market — a space dominated by Novo Nordisk and Eli Lilly.
PFE shares have returned roughly 9% over the past year, with more modest year-to-date gains. The stock has traded in a relatively narrow range, with a 52-week band between approximately $23 and $29. Pfizer's forward dividend yield of nearly 7% remains one of the highest among large-cap pharmaceutical names, although the payout ratio exceeds 100% of trailing earnings, raising questions about dividend sustainability if earnings do not inflect higher. The stock carries a beta near 0.31, indicating defensive characteristics.
Trending AI Robots
For investors seeking a data-driven edge in navigating comparisons like BMY versus PFE, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers across equities, ETFs, and forex, but only those demonstrating the strongest alignment with current market conditions earn a place in this featured section. The bots vary widely in their trading styles — ranging from swing trading to trend following — as well as in timeframes, risk profiles, and statistical track records. Selected bots have shown annualized returns ranging from the mid-teens to over 40% in backtesting, depending on strategy and market regime. Each bot's performance metrics, trade history, and ticker coverage are fully transparent. Explore the Trending AI Robots page to identify which AI strategies align with your market outlook.
Head-to-Head Comparison
Business Model and Revenue Mix: BMY is heavily concentrated in oncology and hematology, with a dominant U.S. revenue base. PFE operates across a broader therapeutic spectrum — vaccines, oncology, rare disease, primary care — and generates a more geographically diversified revenue stream. Both companies share profits from Eliquis, creating a unique co-dependency.
Growth Trajectory: BMY's Growth Portfolio is delivering tangible, double-digit expansion capable of partially offsetting Legacy declines. Pfizer's growth story is more forward-looking, centered on the Metsera obesity pipeline, which may take years to materially contribute to revenue. In the near term, Pfizer's revenue growth has been modest, in the low single digits.
Momentum and Sentiment: BMY has enjoyed notably stronger price momentum over the trailing twelve months, supported by consecutive earnings beats and upward revenue guidance revisions. PFE has traded more range-bound, with sentiment weighed down by post-COVID baseline uncertainty and concerns about dividend coverage.
Risk Factors: Both companies face patent cliffs, drug pricing reform pressure in the U.S., and the ever-present risk of clinical trial setbacks. BMY's higher debt-to-equity ratio (above 2.2x) represents a greater balance-sheet risk compared to Pfizer's more modest leverage (below 0.75x). However, BMY's stronger return on equity — nearly 39% versus Pfizer's roughly 8% — suggests more efficient capital deployment.
Income Appeal: Pfizer's dividend yield of roughly 6.9% meaningfully exceeds BMY's 4.2%, but BMY's payout is better covered by free cash flow. Income-oriented investors face a trade-off between higher current yield (PFE) and stronger dividend sustainability metrics (BMY).
Valuation: Both stocks trade at forward P/E multiples below 10x, indicating that the market prices both for low-growth scenarios. BMY's enterprise-value-to-EBITDA (earnings before interest, taxes, depreciation, and amortization) ratio is slightly higher, reflecting its stronger profitability profile.
Tickeron AI Verdict
Based on observable trend consistency, relative momentum, and fundamental execution, a probabilistic AI-driven assessment would likely tilt in favor of Bristol-Myers Squibb in the current environment. BMY's Growth Portfolio has demonstrated verifiable revenue acceleration, its earnings revisions have trended positively, and its price structure over recent months has shown stronger trend persistence compared to Pfizer's more range-bound behavior. The combination of higher operating margins, stronger return on equity, and better free cash flow coverage of its dividend provides a multi-factor edge. That said, Pfizer's lower leverage, higher dividend yield, and emerging obesity catalyst through the Metsera acquisition represent a contrarian case that could gain traction if metabolic pipeline milestones materialize. As always, such an assessment reflects probabilistic modeling rather than certainty, and relative positioning can shift as new data emerges.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a StrongBuy and PFE is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 3 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s).
- BMY’s FA Score: 3 green, 2 red.
- PFE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 6 TA indicator(s) are bullish while PFE’s TA Score has 4 bullish TA indicator(s).
- BMY’s TA Score: 6 bullish, 3 bearish.
- PFE’s TA Score: 4 bullish, 5 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а +1.65% price change this week, while PFE (@Pharmaceuticals: Major) price change was -0.52% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.61%. For the same industry, the average monthly price growth was +2.10%, and the average quarterly price growth was +4.88%.
Reported Earning Dates
BMY is expected to report earnings on Jul 30, 2026.
PFE is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.61% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| BMY | PFE | BMY / PFE | |
| Capitalization | 126B | 141B | 89% |
| EBITDA | 15B | 17.2B | 87% |
| Gain YTD | 17.887 | 3.810 | 469% |
| P/E Ratio | 17.23 | 19.09 | 90% |
| Revenue | 48.5B | 63.3B | 77% |
| Total Cash | N/A | 13.1B | - |
| Total Debt | 46.4B | 63.7B | 73% |
BMY | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 30 | 12 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 83 | 100 | |
SMR RATING 1..100 | 25 | 77 | |
PRICE GROWTH RATING 1..100 | 19 | 57 | |
P/E GROWTH RATING 1..100 | 53 | 43 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMY's Valuation (4) in the Pharmaceuticals Major industry is in the same range as PFE (5). This means that BMY’s stock grew similarly to PFE’s over the last 12 months.
BMY's Profit vs Risk Rating (83) in the Pharmaceuticals Major industry is in the same range as PFE (100). This means that BMY’s stock grew similarly to PFE’s over the last 12 months.
BMY's SMR Rating (25) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (77). This means that BMY’s stock grew somewhat faster than PFE’s over the last 12 months.
BMY's Price Growth Rating (19) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (57). This means that BMY’s stock grew somewhat faster than PFE’s over the last 12 months.
PFE's P/E Growth Rating (43) in the Pharmaceuticals Major industry is in the same range as BMY (53). This means that PFE’s stock grew similarly to BMY’s over the last 12 months.
| BMY | PFE | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 63% |
| Stochastic ODDS (%) | 2 days ago 58% | 2 days ago 51% |
| Momentum ODDS (%) | 2 days ago 51% | 2 days ago 47% |
| MACD ODDS (%) | 2 days ago 59% | 2 days ago 47% |
| TrendWeek ODDS (%) | 2 days ago 53% | 2 days ago 59% |
| TrendMonth ODDS (%) | 2 days ago 57% | 2 days ago 55% |
| Advances ODDS (%) | 8 days ago 54% | 9 days ago 54% |
| Declines ODDS (%) | 24 days ago 55% | 5 days ago 58% |
| BollingerBands ODDS (%) | 2 days ago 49% | 2 days ago 57% |
| Aroon ODDS (%) | 2 days ago 67% | 2 days ago 59% |
Advertisement
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | +0.77% | ||
| BMY - PFE | 61% Loosely correlated | +1.23% | ||
| MRK - PFE | 55% Loosely correlated | +2.36% | ||
| AMGN - PFE | 53% Loosely correlated | +1.49% | ||
| NVS - PFE | 51% Loosely correlated | +2.00% | ||
| BIIB - PFE | 51% Loosely correlated | +1.46% | ||
More | ||||